NFE2L2 and triple-A syndrome: Considering the demonstrated role of COX-2, iNOS, NF-κB and Nrf2 signalling in the progression and development of AAA (90–92), these studies have highlighted the potential of CHMs in control of various inflammatory processes during AAA and its related vascular conditions, such as atherosclerosis.